2- (2- Chloro- 4- (methylsulfonyl)- 3- ((2,2,2- trifluoroethoxy)methyl)benzoyl)- 1,3- cyclohexanedione (BAY 747)

10/01/2023 - "BAY-747 was investigated in experimental in vivo models of malignant and resistant hypertension (rHT). "
10/01/2023 - "The pharmacokinetic profile of BAY-747 was determined in different species, and it was broadly characterized in pharmacological model systems relevant for vasodilatation and hypertension. "
10/01/2023 - "BAY-747 could be a treatment alternative for patients with hypertension, especially those not responding to standard-of-care therapy."
10/01/2023 - "Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension."
01/01/2023 - "It turned out that BAY 1165747 (BAY-747, 28) could be an ideal treatment alternative for patients with hypertension, especially those not responding to standard anti-hypertensive therapy (resistant hypertension). "

07/27/2021 - "Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy."

07/27/2021 - "We also observed increased inflammation and fibrosis in the skeletal muscle of mdx/mTRG2 mice compared to WT. While gene expression of pro-inflammatory cytokines and some pro-fibrotic markers in the skeletal muscle was reduced following BAY-747 treatment, there was no reduction in infiltration of myeloid immune cells nor collagen deposition. "

07/27/2021 - "We also observed increased inflammation and fibrosis in the skeletal muscle of mdx/mTRG2 mice compared to WT. While gene expression of pro-inflammatory cytokines and some pro-fibrotic markers in the skeletal muscle was reduced following BAY-747 treatment, there was no reduction in infiltration of myeloid immune cells nor collagen deposition. "